FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W202211084> ?p ?o ?g. }

• W202211084 endingPage "339" @default.
• W202211084 startingPage "315" @default.
• W202211084 abstract "In racing and other equine sports, it is possible to increase artificially both the physical capability and the presence of a competitive instinct, using drugs, such as anabolic steroids and agents stimulating the central nervous system. The word doping describes this illegitimate use of drugs and the primary motivation of an equine anti-doping policy is to prevent the use of these substances. However, an anti-doping policy must not impede the use of legitimate veterinary medications and most regulatory bodies in the world now distinguish the control of illicit substances (doping control) from the control of therapeutic substances (medication control). For doping drugs, the objective is to detect any trace of drug exposure (parent drug or metabolites) using the most powerful analytical methods (generally chromatographic/mass spectrometric techniques). This so-called “zero tolerance rule” is not suitable for medication control, because the high level of sensitivity of current screening methods allows the detection of totally irrelevant plasma or urine concentrations of legitimate drugs for long periods after their administration. Therefore, a new approach for these legitimate compounds, based upon pharmacokinetic/pharmacodynamic (PK/PD) principles, has been developed. It involves estimating the order of magnitude of the irrelevant plasma concentration (IPC) and of the irrelevant urine concentration (IUC) in order to limit the impact of the high sensitivity of analytical techniques used for medication control. The European Horserace Scientific Liaison Committee (EHSLC), which is the European scientific committee in charge of harmonising sample testing and policies for racehorses in Europe, is responsible for estimating the IPCs and IUCs in the framework of a Risk Analysis. A Risk Analysis approach for doping/medication control involves three sequential steps, namely risk assessment, risk management, and risk communication. For medication control, the main task of EHLSC in the risk management procedure is the establishment of harmonised screening limits (HSL).The HSL is a confidential instruction to laboratories from racing authorities to screen in plasma or urine for the presence of drugs commonly used in equine medication. The HSL is derived from the IPC (for plasma) or from the IUC (for urine), established during the risk assessment step. The EHSLC decided to keep HSL confidential and to inform stakeholders of the duration of the detection time (DT) of the main medications when screening is performed with the HSL. A DT is the time at which the urinary (or plasma) concentration of a drug, in all horses involved in a trial conducted according to the EHSLC guidance rules, is shown to be lower than the HSL when controls are performed using routine screening methods. These DTs, as issued by the EHSLC (and adopted by the Fédération Equestre Internationale or FEI) provide guidance to veterinarians enabling them to determine a withdrawal time (WT) for a given horse under treatment. A WT should always be longer than a DT because the WT takes into account the impact of all sources of animal variability as well as the variability associated with the medicinal product actually administered in order to avoid a positive test. The major current scientific challenges faced in horse doping control are those instances of the administration of recombinant biological substances (EPO, GH, growth factors etc.) having putative long-lasting effects while being difficult or impossible to detect for more than a few days. Innovative bioanalytical approaches are now addressing these challenges. Using molecular tools, it is expected in the near future that transcriptional profiling analysis will be able to identify some molecular “signatures” of exposure to doping substances. The application of proteomic (i.e. the large scale investigation of protein biomarkers) and metabolomic (i.e. the study of metabolite profiling in biological samples) techniques also deserve attention for establishing possible unique fingerprints of drug abuse." @default.
• W202211084 created "2016-06-24" @default.
• W202211084 creator A5032572523 @default.
• W202211084 date "2010-01-01" @default.
• W202211084 modified "2023-10-10" @default.
• W202211084 title "Veterinary Medicines and Competition Animals: The Question of Medication Versus Doping Control" @default.
• W202211084 cites W1760818055 @default.
• W202211084 cites W1970348676 @default.
• W202211084 cites W1974921104 @default.
• W202211084 cites W1975363425 @default.
• W202211084 cites W1982242232 @default.
• W202211084 cites W2007541193 @default.
• W202211084 cites W2017988883 @default.
• W202211084 cites W2029173116 @default.
• W202211084 cites W2032500136 @default.
• W202211084 cites W2037714321 @default.
• W202211084 cites W2045817658 @default.
• W202211084 cites W2046068927 @default.
• W202211084 cites W2046166203 @default.
• W202211084 cites W2075645483 @default.
• W202211084 cites W2083885283 @default.
• W202211084 cites W2099286542 @default.
• W202211084 cites W2109108975 @default.
• W202211084 cites W2127197640 @default.
• W202211084 cites W2152110465 @default.
• W202211084 cites W2157362057 @default.
• W202211084 cites W2172261908 @default.
• W202211084 cites W4245838196 @default.
• W202211084 cites W4250799221 @default.
• W202211084 doi "https://doi.org/10.1007/978-3-642-10324-7_13" @default.
• W202211084 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20204593" @default.
• W202211084 hasPublicationYear "2010" @default.
• W202211084 type Work @default.
• W202211084 sameAs 202211084 @default.
• W202211084 citedByCount "29" @default.
• W202211084 countsByYear W2022110842012 @default.
• W202211084 countsByYear W2022110842013 @default.
• W202211084 countsByYear W2022110842014 @default.
• W202211084 countsByYear W2022110842015 @default.
• W202211084 countsByYear W2022110842017 @default.
• W202211084 countsByYear W2022110842018 @default.
• W202211084 countsByYear W2022110842019 @default.
• W202211084 countsByYear W2022110842020 @default.
• W202211084 countsByYear W2022110842021 @default.
• W202211084 countsByYear W2022110842022 @default.
• W202211084 countsByYear W2022110842023 @default.
• W202211084 crossrefType "book-chapter" @default.
• W202211084 hasAuthorship W202211084A5032572523 @default.
• W202211084 hasConcept C111113717 @default.
• W202211084 hasConcept C112705442 @default.
• W202211084 hasConcept C144133560 @default.
• W202211084 hasConcept C155202549 @default.
• W202211084 hasConcept C177713679 @default.
• W202211084 hasConcept C185592680 @default.
• W202211084 hasConcept C2780035454 @default.
• W202211084 hasConcept C2909138979 @default.
• W202211084 hasConcept C2909766688 @default.
• W202211084 hasConcept C2910001868 @default.
• W202211084 hasConcept C42972112 @default.
• W202211084 hasConcept C43617362 @default.
• W202211084 hasConcept C71924100 @default.
• W202211084 hasConcept C98274493 @default.
• W202211084 hasConceptScore W202211084C111113717 @default.
• W202211084 hasConceptScore W202211084C112705442 @default.
• W202211084 hasConceptScore W202211084C144133560 @default.
• W202211084 hasConceptScore W202211084C155202549 @default.
• W202211084 hasConceptScore W202211084C177713679 @default.
• W202211084 hasConceptScore W202211084C185592680 @default.
• W202211084 hasConceptScore W202211084C2780035454 @default.
• W202211084 hasConceptScore W202211084C2909138979 @default.
• W202211084 hasConceptScore W202211084C2909766688 @default.
• W202211084 hasConceptScore W202211084C2910001868 @default.
• W202211084 hasConceptScore W202211084C42972112 @default.
• W202211084 hasConceptScore W202211084C43617362 @default.
• W202211084 hasConceptScore W202211084C71924100 @default.
• W202211084 hasConceptScore W202211084C98274493 @default.
• W202211084 hasLocation W2022110841 @default.
• W202211084 hasLocation W2022110842 @default.
• W202211084 hasLocation W2022110843 @default.
• W202211084 hasOpenAccess W202211084 @default.
• W202211084 hasPrimaryLocation W2022110841 @default.
• W202211084 hasRelatedWork W2070799769 @default.
• W202211084 hasRelatedWork W2254638634 @default.
• W202211084 hasRelatedWork W2350556799 @default.
• W202211084 hasRelatedWork W2352350815 @default.
• W202211084 hasRelatedWork W2369345461 @default.
• W202211084 hasRelatedWork W2391414726 @default.
• W202211084 hasRelatedWork W2787695197 @default.
• W202211084 hasRelatedWork W2967470855 @default.
• W202211084 hasRelatedWork W3048352509 @default.
• W202211084 hasRelatedWork W3108281763 @default.
• W202211084 isParatext "false" @default.
• W202211084 isRetracted "false" @default.
• W202211084 magId "202211084" @default.
• W202211084 workType "book-chapter" @default.